

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BrainAurora Medical Technology Limited

脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6681)

VOLUNTARY ANNOUNCEMENT PUBLICATION OF RESEARCH RESULTS ON DOSES OF PEDIATRIC COGNITIVE DIGITAL THERAPEUTICS IN BMC MEDICINE

This announcement is made by BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purposes of keeping the investors informed of the latest update on the business developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Group has recently made significant scientific research achievements in dose-finding research on pediatric cognitive digital therapeutics, and the relevant information is disclosed as follows:

I. RESEARCH RESULTS PUBLISHED IN BMC MEDICINE

Recently, the research titled “Optimal doses of cognitive digital therapeutics for pediatric patients with cognitive impairments: A retrospective study based on big data” jointly conducted by the team of Professor Ni Xin from Beijing Children’s Hospital, Capital Medical University and the scientific research team of the Group were published in BMC Medicine (2025 Journal Impact Factor: 8.7), a top international comprehensive medical journal.

As a retrospective study based on real-world big data, this study included 38,526 children and adolescents (aged from 3 to 18 years) with cognitive impairment who used the Group’s “Brain Function Information Management Platform Software System” (Class II medical device, Registration Certificate No.: Xiang Xie Zhu Zhun 20182210142) and completed at least two weeks of training between 2021 and 2025, systematically characterized the dose-response relationship across three dimensions: daily training duration, weekly training frequency, and total training cycle. The platform contains 123 tasks adapted from classic paradigms, covering four major cognitive domains: perception, attention, memory, and executive function. The Mean Cognitive Index (MCI) adopted by the study as the primary outcome measure reflects comprehensive task performance during training.

Principal findings:

- (1) Optimal daily dose for the overall population: with 0 to 4 minutes per day as the baseline, significant improvement was observed only when daily training exceeded 8 minutes, with 16 to 20 minutes per day corresponding to the highest cognitive performance, representing the optimal daily dose for the overall population. Beyond this range, further extending daily training duration did not yield additional significant benefits.
- (2) Age-and sex-stratified differences: the four subgroups demonstrated different optimal daily doses and total doses:

Age Group	Gender	Optimal Daily Dose	Optimal Total Dose
<10 years old	Male	16 to 20 minutes/day	6 to 7 months
<10 years old	Female	24 to 28 minutes/day	8 to 9 months
≥10 years old	Male	20 to 24 minutes/day	4 to 5 months
≥10 years old	Female	16 to 20 minutes/day	1 to 2 months

- (3) Weekly training frequency: the highest cognitive performance across all four subgroups was observed with 7 days of training per week; for most subgroups, significant improvement was observed only when training was conducted on at least 5 days per week.
- (4) Total intervention cycle: regardless of age and gender, children who received training for more than 1 month demonstrated significant cognitive improvement compared to those who received training for less than 1 month.

The study concluded that this is the first large-scale study to define age – and sex-specific optimal digital training doses for pediatric patients with cognitive impairment, providing strong evidence for individualized cognitive digital therapeutic interventions and serving as a reference for the formulation of future treatment guidelines.

Reference: Liu Y, Liang S, Liang A, et al. Optimal doses of cognitive digital therapeutics for pediatric patients with cognitive impairments: A retrospective study based on big data. BMC Medicine. 2026. DOI: 10.1186/s12916-026-05080-8.

II. SIGNIFICANCE OF THE ABOVE ACHIEVEMENTS TO THE GROUP

Based on real-world data of 38,526 children, this study systematically defined for the first time the optimal digital training doses for different ages and genders, filled the research gap in the dose-response relationship in the field of pediatric cognitive digital therapeutics and provided an evidence-based foundation for individualized precise intervention. The publication of these findings in the top international comprehensive medical journal BMC Medicine reflects the Group's leading capabilities in the field of large-scale real-world data research on cognitive digital therapeutics, thereby further expanding the Group's evidence-based landscape for digital therapeutics to cover diverse populations such as pediatric cognitive impairment.

The Board believes that the above achievements align with the Group's long-term development strategy and should further consolidate the Group's industry-leading position in the fields of digital therapeutics for cognitive impairment and digital therapeutics for pediatric diseases, thereby creating long-term value for shareholders.

The contents of this announcement do not constitute a connected transaction or a notifiable transaction under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Tan Zheng
Chairman and Executive Director

Hong Kong, September 9, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive director; (ii) Mr. Deng Feng, Mr. Yang Fan, and Ms. Wang Jingbo as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive directors.